Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) to Overweight, 'clarity on 2026 growth and no major near-term headwinds for the stock'

Cantor Fitzgerald analyst Prakhar Agrawal upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Neutral to Overweight.

The analyst comments "We are upgrading Madrigal to OW after another very strong quarter for Rezdiffra outperforming high investor expectations - Rezdiffra 3Q US net sales of $287M vs. FactSet consensus of $247M and buyside expectations of $255-$260M. Until now, we have been on the sidelines and have had a glass-half empty view of the stock, based on valuation and skepticism around navigating GLP-1 headwinds. However, with clarity on 2026 growth and no major near-term headwinds for the stock, we are less valuation-sensitive and upgrade to OW. Importantly, we could also see profitability in 2026 (even 4Q 25 could be net income positive). With meaningful cash flow generation in ‘26/’27, we expect Madrigal to be even more aggressive on BD to augment the pipeline."

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $412.35 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Aurora Spine settles patent dispute, secures $600K insider loan
• Full Circle Lithium closes $5.14M private placement